natgillin/translations-raw huggingface dataset:
Other medicinal products: Substances that are largely eliminated via CYP2C19 metabolism, such as diazepam, propranolol and omeprazole may have reduced clearance upon co-administration of modafinil and may thus require dosage reduction. 
Druga zdravila: Učinkovine, ki se večinoma izločajo prek presnove s CYP2C19, kot so diazepam, propranolol in omeprazol, imajo lahko zmanjšane očistke ob sočasnem dajanju modafinila, zato bo morda potrebno zmanjšanje odmerka.
Modafinil is a wakefulness promoting agent. 
Modafinil je sredstvo za spodbujanje budnosti.
If psychotic or manic symptoms occur, discontinuation of modafinil may be required. 
Če se pojavijo psihotični ali manični simptomi, bo morda treba zdravljenje prekiniti.
Gonzagagasse 16/16, A-1010 Vienna, Austria 
Torrex Chiesi Pharma GmbH, Gonzagagasse 16/16, A-1010 Vienna, Austria
Reproductive toxicity studies conducted in rats and rabbits showed an increased incidence in skeletal variations (changes in the numbers of ribs and delayed ossification), embryo-fetal lethality (periimplantation loss and resorptions) and some evidence of an increase in stillbirths (rats only), in the absence of maternal toxicity, at clinically relevant exposures. 
Študije reproduktivne toksičnosti, izvedene pri podganah in kuncih, so pokazale povečano pogostost skeletnih sprememb (spremembe v številu reber in zakasnela osifikacija), embrio-fetalno smrtnost
Modafinil is metabolized by the liver. 
Modafinil se presnavlja v jetrih.
Anticoagulants: Due to possible suppression of CYP2C9 by modafinil the clearance of warfarin may be decreased when modafinil is administered concomitantly. 
Antikoagulansi: Zaradi možne supresije CYP2C9 z modafinilom je očistek varfarina lahko zmanjšan, če se hkrati jemlje tudi modafinil.
Uncommon: minor allergic reaction (e.g., hayfever symptoms) Unknown: Angioedema, urticaria (hives).Hypersensitivity reactions (characterised by features such as fever, rash, lymphadenopathy and evidence of other concurrent organ involvement) 
Občasni: manjše alergijske reakcije (npr. simptomi senenega nahoda) Neznana: angioedem, urtikarija (koprivnica), preobčutljivostne reakcije (za katere so značilni povišana telesna temperatura, izpuščaj, limfadenopatija in dokazi sočasne vključenosti drugih organov)
Unknown: serious skin reactions, including erythema multiforme, Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS). 
Neznana: resne kožne reakcije, vključno z multiformnim eritemom, Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo in izpuščajem zaradi zdravila z eozinofilijo ter sistemskimi simptomi (DRESS - Drug Rash with Eosinophilia and Systemic Symptoms)
Positive de-challenge and/or re-challenge was reported in some cases. 
Pri številnih primerih so poročali o pozitivnih rezultatih odtegnitve in/ali ponovnega izziva.
Obstructive Sleep Apnoea 
Obstruktivna apneja med spanjem
Patients treated with modafinil should be carefully monitored for the appearance or worsening of psychotic or manic symptoms. 
Bolniki, ki so zdravljeni z modafinilom, naj se skrbno nadzorujejo za pojav ali poslabšanje psihotičnih ali maničnih simptomov.
Other associated manifestations included myocarditis, hepatitis, liver function test abnormalities, haematological abnormalities (e.g., eosinophilia, leukopenia, thrombocytopenia), pruritus, and asthenia. 
Druge povezane manifestacije so vključevale miokarditis, hepatitis, nenormalnosti pri testiranju delovanja jeter, hematološke nenormalnosti (npr. eozinofilijo, levkopenijo, trombocitopenijo), pruritus in astenijo.
The Committee considered that the evidence for clinically significant efficacy of modafinil-containing products in excessive sleepiness associated with obstructive sleep disorder, shift work sleep disorder and idiopathic hypersomnia is very limited, and therefore any potential benefit for patients is outweighed by the identified risks. 
Odbor je menil, da so dokazi za klinično pomembno učinkovitost zdravil, ki vsebujejo modafinil, za indikacijo čezmerne zaspanosti v povezavi z obstruktivno apnejo med spanjem, motnjo spanja zaradi izmenskega dela in idiopatsko hipersomnijo zelo omejeni, zato znana tveganja odtehtajo vse možne koristi.
Patients treated with modafinil should be carefully monitored for the appearance or worsening of aggressive or hostile behaviour. 
Bolniki, ki so zdravljeni z modafinilom, naj bodo skrbno nadzorovani za pojav ali poslabšanje agresivnega ali sovražnega vedenja.
Potential risk of abuse, misuse and diversion 
Možno tveganje zlorabe, napačne uporabe in rekreativne uporabe
Uncommon: dyskinesia, hypertonia, hyperkinesia, amnesia, migraine, tremor, vertigo, CNS stimulation, hypoaesthesia, incoordination, movement disorder, speech disorder, taste perversion 
Občasni: diskinezija, hipertonija, hiperkinezija, amnezija, migrena, tremor, vrtoglavica, stimulacija osrednjega živčevja, hipestezija, nekoordiniranost, motnje gibanja, motnje govora, sprememba okusa
If symptoms occur, discontinuation of modafinil may be required. 
Če se simptomi pojavijo, bo morda treba prekiniti zdravljenje z modafinilom.
In clinical trials, with the exception of headache, dizziness and cataplexy, all other nervous system related terms occurred almost exclusively in the modafinil treated patients. 
V kliničnih preskušanjih so se izrazi v zvezi z živčevjem (z izjemo glavobola, omotice in katapleksije) pojavljali skoraj izključno pri bolnikih, zdravljenih z modafinilom.
Induced emesis or gastric lavage should be considered. 
Razmisli naj se o inducirani emezi ali izpiranju želodca.
Do not take Modafinil containing medicinal products if you: 
Ne jemljite zdravil, ki vsebujejo modafinil:
Marketing Authorisation Holder and manufacturers [See Annex I - To be completed nationally] 
Imetnik dovoljenja za promet z zdravilom in izdelovalci [Glejte Dodatek I - Izpolni država članica]
Narcolepsy 
Narkolepsija
You will need to consider other birth control methods while taking Modafinil containing medicinal products, and for two months after stopping treatment, because Modafinil containing medicinal products reduces their effectiveness. 
Razmisliti boste morali o drugih metodah kontracepcije medtem ko jemljete zdravila, ki vsebujejo modafinil, in dva meseca po prenehanju zdravljenja,
Off label use 
Uporaba zunaj obsega indikacij
The cardiovascular profile of modafinil remains the most relevant concern in the OSA population given the already elevated baseline risk. 
Srčno-žilni profil modafinila ostaja najpomembnejši problem v populaciji bolnikov z OSA, ki imajo večje izhodiščno tveganje.
It is especially important if you are taking any of the following medicines as well as Modafinil containing medicinal products: 
To je še posebej pomembno, če jemljete katerakoli od naslednjih zdravil skupaj z zdravili, ki vsebujejo modafinil: - hormonska kontracepcijska sredstva (vključno s kontracepcijskimi tabletami, vsadki,
• The Committee considered that the evidence for clinically significant efficacy of modafinilcontaining products in excessive sleepiness associated with obstructive sleep disorder, shift work sleep disorder and idiopathic hypersomnia is very limited, and therefore any potential benefit for patients is outweighed by the identified risks. 
• Odbor je menil, da so dokazi za klinično pomembno učinkovitost zdravil, ki vsebujejo modafinil, za indikacijo čezmerne zaspanosti v povezavi z obstruktivno apnejo med spanjem, motnjo spanja zaradi izmenskega dela in idiopatsko hipersomnijo zelo omejeni, zato znana tveganja odtehtajo vse možne koristi.
Appropriate data on the cardiovascular safety of modafinil in OSA patients continues to be considered necessary to assess the magnitude of the concern. 
Za oceno obsega problema so še vedno potrebni primerni podatki o srčnožilni varnosti modafinila pri bolnikih z OSA.
PACKAGE LEAFLET: INFORMATION FOR THE USER Modafinil containing medicinal products 100 mg Tablets Modafinil containing medicinal products 200 mg Tablets Modafinil 
Zdravila, ki vsebujejo modafinil, 100 mg tablete Zdravila, ki vsebujejo modafinil, 200 mg tablete modafinil
Higher concentrations of one of the circulating metabolites, modafinil sulfone, are present in children and adolescents as compared to adults. 
Otroci in mladostniki imajo večje koncentracije enega od presnovkov, modafinilijevega sulfona, v krvnem obtoku kot odrasli.
Patients treated with modafinil should be carefully monitored for the appearance or worsening of suicide-related behaviour. 
Bolnike, ki so zdravljeni z modafinilom, je treba skrbno nadzorovati za pojav ali poslabšanje vedenja, povezanega s samomori.
Renal and urinary disorders Uncommon: abnormal urine, urinary frequency 
Bolezni sečil Občasni: nenormalen urin, pogostost uriniranja
Respiratory, thoracic and mediastinal disorders Uncommon: dyspnoea, increased cough, asthma, epistaxis, rhinitis 
Bolezni dihal, prsnega koša in mediastinalnega prostora Občasni: dispneja, povečano kašljanje, astma, epistaksa, rinitis
The cardiovascular profile of modafinil is of particular concern in the OSA population given the already elevated baseline risk. 
Srčno-žilni profil modafinila zlasti vzbuja skrb v populaciji bolnikov z OSA, ki imajo večje izhodiščno tveganje.
Member State 
ČLANICAH
Furthermore, it was noted that differences likely to be clinically significant in objective measures of sleepiness between modafinil and placebo were limited to a very small percentage of the patient population in the modafinil clinical trials. 
Poleg tega so ugotovili, da so bile v kliničnih preskušanjih modafinila razlike med modafinilom in placebom, ki so bile verjetno klinično pomembne glede na objektivna merila zaspanosti, omejene na zelo majhen odstotek populacije bolnikov.
Common: abdominal pain, nausea, dry mouth, diarrhoea, dyspepsia, constipation Uncommon: flatulence, reflux, vomiting, dysphagia, glossitis, mouth ulcers 
Pogosti: abdominalne bolečine, navzea, suha usta, diareja, dispepsija, zaprtje Občasni: flatulenca, refluks, bruhanje, disfagija, glositis, ustne razjede
Serious adverse reactions affecting the nervous system have been reported spontaneously in association with modafinil, including cerebrovascular disorders, convulsions and extrapyramidal symptoms. 
V spontanih poročilih so bili v zvezi z modafinilom navedeni resni neželeni učinki, ki vplivajo na živčevje, vključno s cerebrovaskularnimi boleznimi, konvulzijami in ekstrapiramidalnimi simptomi.
[See Annex I - To be completed nationally] {Name and address} <{tel}> <{fax}> <{e-mail}> 
[Glejte Dodatek I - podatke je treba dopolniti v posameznih državah.]
The signs may include: o mood swings or abnormal thinking, o aggression or hostility, o forgetfulness or confusion, o feeling of extreme happiness, o over-excitement or hyperactivity, o anxiety or nervousness, o depression, suicidal thoughts or behaviour, o agitation or psychosis (a loss of contact with reality which may include delusions or sensing things that are not real), feeling detached or numb, or personality disorder. 
Ti znaki lahko vključujejo: o nihanje razpoloženja ali nenormalno razmišljanje; o agresijo ali sovražnost; o pozabljivost ali zmedenost; o občutek ekstremne sreče; o pretirano vzburjenost ali hiperaktivnost; o tesnobnost ali nervoznost; o depresijo, samomorilne misli ali vedenje;
Blood pressure and heart rate should be regularly monitored in patients receiving modafinil. 
Pri bolnikih, ki jemljejo modafinil, naj se redno nadzorujeta krvni tlak in utrip.
Suicide-related behaviour (including suicide attempts and suicidal ideation) has been reported in patients treated with modafinil. 
Pri bolnikih, zdravljenih z modafinilom, so poročali o s samomorom povezanem vedenju (vključno s poskusi samomora in samomorilnimi mislimi).
Important information about some of the ingredients of Modafinil containing medicinal products [To be completed nationally]. 
Pomembne informacije o nekaterih sestavinah zdravil, ki vsebujejo modafinil [Izpolni država članica]
Following a request from the MAH, the CHMP convened a Scientific Advisory Group (SAG) CNS during the re-examination procedure. 
CHMP je v postopku ponovnega pregleda po zahtevku imetnika dovoljenja za promet z zdravilom sklical znanstveno svetovalno skupino (SAG) za klinično nevrologijo.
• Have an irregular heartbeat. 
• če imate nereden srčni utrip;
The following adverse reactions have been reported in clinical trials and/or post-marketing experience. 
V kliničnih preskušanjih in/ali izkušnjah po dajanju zdravila v promet so poročali o naslednjih neželenih učinkih.
Rare cases of serious or life-threatening rash, including Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN), and Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) have been reported in adults and children in worldwide post-marketing experience. 
Poročali so o redkih primerih smrtno nevarnega izpuščaja, vključno s Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo ter o izpuščaju zaradi zdravil z eozinofilijo in sistemskimi simptomi pri otrocih in odraslih po postmarketinških izkušnjah z vsega sveta.
A total of 16 cases of Stevens Johnson Syndrome/Toxic Epidermal Necrolysis/Erythema Multiforme have been reported in a post-marketing setting. 
V obdobju trženja zdravila so poročali o 16 primerih Stevens-Johnsonovega sindroma ali toksične epidermalne nekrolize ali mutiformnega eritema.
General disorders and administration site conditions Common: asthenia, chest pain Uncommon: peripheral oedema, thirst 
Splošne težave in spremembe na mestu aplikacije Pogosti: astenija, bolečina v prsnem košu Občasni: periferni edem, žeja
Musculoskeletal and connective tissue disorders Uncommon: back pain, neck pain, myalgia, myasthenia, leg cramps, arthralgia, twitch 
Bolezni mišično-skeletnega sistema in vezivnega tkiva Občasni: bolečine v hrbtu, bolečine v vratu, mialgija, miastenija, krči v nogah, artralgija, trzanje
Uncommon: sleep disorder, emotional lability, decreased libido, hostility, depersonalisation, personality disorder, abnormal dreams, agitation, aggression, suicidal ideation. 
Pogosti: nervoza, insomnija, anksioznost, depresija, nenormalno mišljenje, zmedenost Občasni: motnje spanja, čustvena labilnost, zmanjšan libido, sovražnost, depersonalizacija, osebnostna motnja, nenormalne sanje, agitacija, agresija, samomorilne misli Redki: halucinacije, manija, psihoza
• Calcium channel blockers or beta-blockers for high blood pressure or heart problems (e.g. amlodipine, verapamil or propranalol). 
Med zdravljenjem bo vaš zdravnik nadzoroval čas strjevanja krvi; - zaviralce kalcijevih kanalčkov ali zaviralce receptorjev beta za visok krvni tlak ali težave s srcem (npr. amlodipin, verapamil ali propranalol); - statine za zniževanje ravni holesterola (npr. atorvastatin ali simvastatin).
Abuse, misuse and diversion 
Zloraba, napačna uporaba in rekreativna uporaba
Particularly for serious skin disorders, data is indicative of a higher incidence in the paediatric population. 
Podatki kažejo večjo pojavnost v pediatrični populaciji, zlasti resnih kožnih bolezni.
Cardiovascular adverse events such as hypertension and arrhytmias are documented in association with modafinil. 
Dokumentirana je povezava med modafinilom in srčno-žilnimi dogodki, kot so hipertenzija in aritmije.
Serious nervous system and psychiatric related events such as suicidal ideation, psychotic episodes, and depression have also been identified in association to modafinil. 
Z modafinilom so povezani tudi resni učinki na živčevje in psihiatrični učinki, kot so samomorilne misli, psihotične epizode in depresija.
Gonzagagasse 16/16, 1010, Vienna, Austria 
Torrex Chiesi Pharma GmbH, Gonzagagasse 16/16, 1010, Vienna,
Cephalon GmbH Landsberger Straße 94 80339 München, Germany 
Cephalon GmbH Landsberger Straße 94
Bipolar disorders 
Bipolarne motnje
CEPHALON France 20, rue Charles Martigny 94701 Maisons-Alfort Cedex 
CEPHALON France 20, rue Charles Martigny 94701 Maisons-Alfort Cedex France
Uncommon: sweating, rash, acne, pruritis 
Občasni: potenje, izpuščaj, akne, pruritus
The dosage of modafinil should be reduced by half in patients with severe hepatic impairment. 
Pri bolnikih s hudo jetrno okvaro je treba odmerek modafinila prepoloviti.
Product name Strength Pharmaceutical form 
Farmacevtska oblika
BEFORE YOU TAKE MODAFINIL CONTAINING MEDICINAL PRODUCTS 
SHRANJEVANJE ZDRAVIL, KI VSEBUJEJO MODAFINIL
Serious rash requiring hospitalisation and discontinuation of treatment has been reported with the use of modafinil occurring within 1 to 5 weeks after treatment initiation. 
Hudi izpuščaji, vključno s Stevens-Johnsonovim sindromom, toksično epidermalno nekrolizo in izpuščajem zaradi zdravil z eozinofilijo in sistemskimi simptomi Pri uporabi modafinila so poročali o hudem izpuščaju, ki je zahteval hospitalizacijo in prekinitev zdravljenja, pojavil pa se je od enega do pet tednov po začetku zdravljenja.
Take special care with Modafinil containing medicinal products if you 
Bodite posebno pozorni pri uporabi zdravil, ki vsebujejo modafinil:
ANNEX III SUMMARY OF PRODUCT CHARACTERISTICS AND PACKAGE LEAFLET 
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA IN NAVODILO ZA UPORABO
HOW TO TAKE MODAFINIL CONTAINING MEDICINAL PRODUCTS Always take Modafinil containing medicinal products exactly as your doctor has told you. 
Pri jemanju zdravil, ki vsebujejo modafinil, natančno upoštevajte zdravnikova navodila.
MODIODAL 100 mg tablets 
MODIODAL 100 mg/tabl tablete
The higher rate of adverse events observed in the modafinil group during the OSA trials is of particular concern, given the known cardiovascular risks in this population. 
Glede na znana tveganja srčno-žilnih bolezni v tej populaciji je zlasti problematična višja stopnja neželenih učinkov v skupini, ki je prejemala modafinil med preskušanji pri OSA.
Numbness or tingling of the hands or feet (‘pins and needles'). 
materničnimi vložki (IUV) in obliži).
NAME OF THE MEDICINAL PRODUCT Modafinil - containing medicinal products (see Annex I) products 100 mg tablets Modafinil - containing medicinal products (see Annex I) products 200 mg tablets See Annex I - To be completed nationally. 
Zdravila, ki vsebujejo modafinil (glejte Dodatek I) 100 mg tablete.
The effects of Balaxur were first tested in experimental models before being studied in humans. 
Učinki zdravila Balaxur so bili najprej preskušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The company that applied for authorisation is Merz Pharmaceuticals GmbH, Germany. 
Zahtevo za dovoljenje za promet z zdravilom je vložila nemška družba Merz Pharmaceuticals GmbH.
The company informed the CHMP that there are no patients currently included in clinical trials with Balaxur in the European Union. 
Družba je odbor CHMP obvestila, da v Evropski uniji v klinična preskušanja zdravila Balaxur trenutno ni vključenih bolnikov.
Balaxur is a medicine that contains two active substances, memantine hydrochloride and donepezil hydrochloride. 
Balaxur je zdravilo, ki vsebuje dve zdravilni učinkovini, memantinijev hidroklorid in donepezilijev hidroklorid.
On 18 October 2012, the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion, recommending the refusal of the marketing authorisation for the medicinal product Balaxur, intended for the treatment of moderate to moderately severe Alzheimer's disease in patients who are already taking memantine and donepezil. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je 18. oktobra 2012 sprejel negativno mnenje, s katerim priporoča zavrnitev odobritve dovoljenja za promet z zdravilom Balaxur, ki naj bi se uporabljalo za zdravljenje zmerne do zmerno hude Alzheimerjeve bolezni pri bolnikih, ki že prejemajo memantin in donepezil.
Therefore, the CHMP was of the opinion that the benefits of Balaxur did not outweigh its risks and recommended that it be refused marketing authorisation. 
Posledično je odbor CHMP menil, da koristi zdravila Balaxur ne odtehtajo z njim povezanih tveganj, zato je priporočil zavrnitev dovoljenja za promet z zdravilom.
Balaxur is a combination treatment containing two active substances which are already authorised in the EU to treat the symptoms of Alzheimer's disease. 
Zdravilo Balaxur je kombinirano zdravilo z dvema zdravilnima učinkovinama, ki sta v EU že odobreni za zdravljenje simptomov Alzheimerjeve bolezni.
What is Balaxur? 
Kaj je zdravilo Balaxur?
Balaxur was expected to be used to treat moderate to moderately severe Alzheimer's disease, in patients who are already taking a daily dose of 20 mg memantine and 10 mg donepezil. 
Zdravilo Balaxur naj bi se uporabljalo za zdravljenje zmerne do zmerno hude Alzheimerjeve bolezni pri bolnikih, ki že prejemajo dnevni odmerek 20 mg memantina in 10 mg donepezila.
What was Balaxur expected to be used for? 
Za kaj naj bi se zdravilo Balaxur uporabljalo?
How is Balaxur expected to work? 
Kako naj bi zdravilo Balaxur delovalo?
Changes in the way glutamate transmits signals within the brain have been linked to the memory loss seen in Alzheimer's disease, and over-activity of the NMDA receptors can result in cell damage or death. 
Spremembe načina, kako glutamat prenaša signale v možganih, se povezujejo z izgubo spomina, kakršna je pri Alzheimerjevi bolezni, prekomerna aktivnost receptorjev
90 (3 x 30) tablets (multipack) 
90 (3 x 30) tablet (skupna pakiranja)
Do not use on canaries. 
Ne uporabljajte pri kanarčkih.
Imidacloprid is toxic for birds, especially canaries. 
Imidakloprid je toksičen za ptice, zlasti za kanarčke.
Date of first authorisation: 02/04/2003. 
Datum pridobitve dovoljenja za promet: 02/04/2003.
ATCvet code: QP54AB52. 
Oznaka ATC vet: QP54AB52.
These signs disappear without further treatment. 
Ti znaki izginejo brez nadaljnjega zdravljenja.
Wash hands thoroughly after use. 
Po dajanju si temeljito umijte roke.
In the study these reactions were common (seen in 2 of 106 treated dogs). 
V raziskavah so bile take reakcije pogoste (pri 2 od 106 zdravljenih psih).
It is a parasiticide which is active against many internal and external parasites. 
Je paraziticid, ki deluje na mnoge notranje in zunanje zajedavce.
It is advisable to prevent auto-coprophagia between the two treatments in order to prevent possible reinfection. 
Priporočljivo je preprečiti avto-koprofagijo med obema zdravljenjema, da preprečimo morebitno ponovno okužbo.
Date of last renewal: 14/01/2013. 
Datum zadnjega podaljšanja dovoljenja za promet: 14/01/2013.
Do not eat, drink or smoke during application. 
Med nanosom ne jejte, pijte in kadite.
Efficacy against adult Dirofilaria repens has not been tested under field conditions. 
Učinkovitost proti odraslim oblikam Dirofilaria repens v terenskih razmerah ni bila testirana.
Apply only to undamaged skin. 
Nanašajte le na nepoškodovano kožo.
Especially severe cases may require more prolonged and more frequent treatment. 
V primeru hudih okužb je potrebno podaljšano in pogostejše zdravljenje.
Microfilaria 
mikrofilarije
The safety of the product has only been evaluated in dogs classified as either Class 1 or 2 for heartworm disease in laboratory studies and in a few Class 3 dogs in a field study. 
Varnost zdravila pri dirofilariozi je bila ocenjena le pri psih, klasificiranih kot razred 1 ali 2 v laboratorijskih študijah in pri nekaterih psih razreda 3 v terenskih študijah.
See sections 4.5 and 6.6. 
Glejte poglavji 4.5 in 6.6.
Weight of dog [kg] 
Teža psa [kg]
The product's efficacy has not been tested in ferrets weighing over 2 kg and therefore the duration of effect might be shorter in these animals. 
Testiranje učinkovitosti zdravila ni bilo opravljeno na belih dihurjih, težjih od 2 kg, zato je pri njih lahko učinkovanje zdravila krajše.
A further veterinary examination 30 days after treatment is recommended as some animals may require a second treatment. 
Priporočamo pregled pri veterinarju 30 dni po dajanju zdravila, ker bo pri nakaterih živalih potrebno zdravljenje ponoviti.
Avoid contact with skin, eyes or mouth. 
Preprečite stik pripravka s kožo, očmi ali usti.